Syngene International has entered into a non-exclusive partnering agreement with Zumutor Biologics, an emerging immuno-oncology company. The partnership enables Syngene to access Zumutor’s proprietary naïve human phage/yeast display library.

The collaboration further enhances Syngene’s market-leading capabilities in discovery biology, providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery.

Under the terms of the agreement, Syngene will screen target antigens against Zumutor’s proprietary human antibody libraries to identify and characterise novel antibody clones, which will be further developed by Syngene towards novel biotherapeutics programs for its partners.
 
“We will use the proprietary antibody display platform to enhance Syngene’s discovery programmes. Our antibody engineering expertise and experience enables us to optimise any lead to evolve into a best-in-class differentiated molecule”, said Kavitha Iyer Rodrigues, Founder-CEO, Zumutor Biologics.

Commenting on the collaboration, Dr. Manoj Nerurkar, chief operating officer, Syngene International, said, that being a pioneer in discovery research, we see Discovery Biology as one of our growth drivers. This partnership will expand our existing portfolio of therapeutic antibody discovery platforms for our clients.”

Zumutor Biologics Inc. focuses on novel monoclonal antibody therapeutics against innate immunity targets. Its high diversity human antibody libraries serve as powerhouse for developing novel monoclonal antibody therapeutics targeting various immune-oncology pathways. The product pipeline constitutes unique immuno-oncotherapeutics that target innate immunity and regulate tumor micro environment. Its lead candidate in prostate cancer has revealed significant tumor reduction, when applied alone and in combination with check point inhibitor in mouse efficacy study.